ClinicalTrials.gg
CompletedNCT00934856Updated Apr 6, 2017Results posted

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

A Phase 1/2 interventional study of Docetaxel and Pertuzumab in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 8 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-06.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
98
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.

Enrollment
92nd of 248
98 · median 68
Started
2009
with 12 others
Phase 1/2
17 of 264
2 open now
Registered
175th of 264
by date
Lead sponsor
16 of 264
Hoffmann-La Roche

Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 92nd largest by enrollment of the 248 interventional ones that give a count, is one of 13 that started in 2009, is one of 17 in phase 1/2, and was the 175th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies testing docetaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, multi-center, non-randomized study of the safety and tolerability of the combination of T-DM1 plus docetaxel for the treatment of participants with metastatic breast cancer (MBC) and of T-DM1 plus docetaxel with or without pertuzumab, for the treatment of participants with locally advanced breast cancer (LABC). The study comprises an initial dose finding (feasibility) part to determine the maximum tolerated dose (MTD) of T-DM1 and docetaxel, followed by an extension part aiming to consolidate the safety and efficacy of the recommended docetaxel/T-DM1 combination regimen.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status 0-1 (ECOG performance status of 2 will be allowed if only due to debilitating bone disease)
  • -positive or locally advanced breast cancer

For MBC participants:

  • Documented metastatic or inoperable locally advanced (without meeting LABC criteria) disease, amenable for treatment with docetaxel
  • History of disease progression within 3 months prior to study entry

For LABC participants:

  • Newly diagnosed locally advanced breast cancer, Stage IIA-IIIC (American Joint Committee on Cancer [AJCC] staging system)

Exclusion criteria

Exclusion Criteria:

  • Significant cardiac disease
  • Inadequate bone marrow, liver or renal function

For MBC participants:

  • Participants must not have received radiotherapy for the treatment of or locally recurrent/advanced disease other than for the relief of pain in progressing metastatic bone lesions and/or
  • Brain metastases that are untreated, symptomatic or require therapy to control symptoms; or any radiation, surgery, or other therapy to control symptoms from brain metastasis within 2 months of the first study treatment.

For LABC participants:

  • Clinically or radiologically detectable metastasis (M1 disease)
  • Participants for whom surgery as primary intent procedure is the best option to treat their disease
  • Participants must not have received any systemic or loco-regional anti-cancer therapy for the treatment of locally advanced disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (over 2 days)

    Participants with human epidermal growth factor receptor 2 (HER2)-positive MBC will receive docetaxel (Doc) 75 milligrams per square meter (mg/m\^2) intravenous (IV) infusion on Day 1 and T-DM1 2.4 milligrams per kilogram (mg/kg) IV infusion on Day 2 of Cycle 1 followed by T-DM1 75 mg/m\^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 75 mg/m\^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.

    Drug: Docetaxel · Drug: Trastuzumab emtansine

  • Experimental
    MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (over 2 days)

    Participants with HER2-positive MBC will receive docetaxel 60 mg/m\^2 IV infusion on Day 1 and T-DM1 2.4 mg/kg IV infusion on Day 2 of Cycle 1 followed by T-DM1 60 mg/m\^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m\^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.

    Drug: Docetaxel · Drug: Trastuzumab emtansine

  • Experimental
    MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (same day)

    Participants with HER2-positive MBC will receive docetaxel 60 mg/m\^2 IV infusion and T-DM1 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m\^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.

    Drug: Docetaxel · Drug: Trastuzumab emtansine

  • Experimental
    MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (same day)

    Participants with HER2-positive MBC will receive docetaxel 60 mg/m\^2 IV infusion and T-DM1 3.6 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m\^2 will be stopped and T-DM1 3.6 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.

    Drug: Docetaxel · Drug: Trastuzumab emtansine

  • Experimental
    LABC: T-DM1 + Doc (Doublet Regimen)

    Participants with HER2-positive LABC will receive T-DM1 3.6 mg/kg IV infusion and docetaxel 60/75/100 mg/m\^2 IV infusion on Day 1 of each 3-week cycle, for 6 cycles. Study treatment will be administered for up to 6 cycles or until unacceptable toxicity, and prior to surgery.

    Drug: Docetaxel · Drug: Trastuzumab emtansine

  • Experimental
    LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen)

    Participants with HER2-positive LABC will receive T-DM1 3.6 mg/kg Iv infusion, docetaxel 60/75 mg/m\^2 IV infusion, and pertuzumab 840 mg (for Cycle 1) or 420 mg (for remaining cycles) IV infusion on Day 1 of each 3-week cycle, for 6 cycles. Study treatment will be administered for up to 6 cycles or until unacceptable toxicity, and prior to surgery.

    Drug: Docetaxel · Drug: Pertuzumab · Drug: Trastuzumab emtansine

Interventions

  • Docetaxel will be administered on Day 1 of each 3-week cycle at a dose specified in the respective arms (as per summary of product characteristics \[SmPC\]).

  • Pertuzumab at a loading dose of 840 mg IV infusion on Day 1 of Cycle 1 followed by maintenance dose of 420 mg IV infusion on Day 1 of each 3-week cycle.

  • T-DM1 will be administered on Day 1 or Day 2 of each 3-week cycle at a dose specified in the respective arms.

    Also known as: T-DM1

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicity (DLT) - MBC and LABC Feasibility Population

    DLTs included (as per National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] grading): Grade 4 thrombocytopenia, thrombocytopenia of any grade with concurrent hemorrhage or requiring blood platelet transfusion, or thrombocytopenia not recovered by Day 21 to at least 100,000/microliter (mcL); Grade 4 neutropenia lasting for more than 7 days; Febrile neutropenia; Grade greater than or equal to (\>/=) 3 neurotoxicity in the form of peripheral neuropathy or peripheral neurotoxicity not improving to baseline or Grade less than or equal to (\</=) 1 by Day 21; Any non-hematological toxicity of Grade \>/= 3 except for alopecia, fever, and chills, not improving to baseline or Grade \</=1 by Day 21, despite adequate toxicity management; Any subjective intolerable toxicity felt by the investigator to be related to either study treatment; Any other treatment-related toxicity prohibiting the start of the Cycle 2 on Day 22; Fulminant skin rash.

    Time frame: Cycle 1 (up to 21 days)

  2. Percentage of Participants With Adverse Events (AEs) or Serious AEs (SAEs) - MBC and LABC Population

    An AE is any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

    Time frame: Baseline up to 28 days after last dose for MBC participants and for LABC participants who could not undergo surgery, and up to 6 weeks post-surgery for LABC participants who underwent surgery (maximum up to approximately 3 years)

Secondary outcomes

  1. Percentage of Participants With Progression-Free Survival (PFS) Event - MBC Population

    PFS was defined as the time interval between the date of the start of treatment and the date of first documentation of progressive disease (PD) or death from any cause, whichever occurred first. Response was based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 (v1.0). For target lesions (TLs), PD was at least a 20 percent (%) increase in the sum of longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more lesions. For non-target lesions (NTLs), PD was the appearance of one or more new lesions and/or unequivocal progression of existing NTLs. Data for participants without PD or death was censored at the time of the last response assessment. Percentage of participants with PFS event was calculated as the (number of participants with PFS event \[PD or death\]) divided by (total number of participants), and then multiplied by 100.

    Time frame: Baseline until disease progression or death (up to approximately 3 years)

  2. PFS - MBC Population

    PFS was defined as the time interval between the date of the start of treatment and the date of first documentation of PD or death from any cause, whichever occurred first. Response was based on RECIST v1.0. For TLs, PD was at least a 20 % increase in the sum of LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more lesions. For NTLs, PD was the appearance of one or more new lesions and/or unequivocal progression of existing NTLs. Median PFS time was calculated using Kaplan-Meier estimates. Data for participants without PD or death was censored at the time of the last response assessment.

    Time frame: Baseline until disease progression or death (up to approximately 3 years)

  3. Percentage of Participants With a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) - MBC Population

    BOR was defined as CR or PR recorded from baseline until disease progression/recurrence according to RECIST v1.0 criteria. For TLs, CR was defined as the disappearance of all TLs, and PR was defined as at least a 30% decrease in the sum of LDs of the TLs, taking as a reference the baseline (BL) sum of LDs. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. Percentage of participants with BOR rate was calculated as the (number of participants with CR or PR) divided by (total number of participants), and then multiplied by 100. The 95% confidence interval (Cl) was determined using the Pearson-Clopper method.

    Time frame: Baseline until disease progression or recurrence (up to approximately 3 years)

  4. Percentage of Participants With Treatment Failure - MBC Population

    Treatment failure was defined as the discontinuation of treatment for any reason, including the following qualifying events: PD, death from any cause, withdrawal from study treatment, or initiation of nonprotocol anti-cancer therapy. Percentage of participants with treatment failure was calculated as the (number of participants with treatment failure) divided by (total number of participants), and then multiplied by 100.

    Time frame: Baseline until end of treatment (up to 39.8 months)

  5. Time to Treatment Failure (TTF) - MBC Population

    TTF was defined as the time interval between the date of start of treatment and the date of PD, death from any cause, withdrawal from study treatment, or initiation of non-protocol anti-cancer therapy, whichever occurred first. Participants without an event at the time of the analysis were censored at the date of the last follow-up assessment. Median TTF was estimated using the Kaplan-Meier method.

    Time frame: Baseline until end of treatment (up to 39.8 months)

  6. Percentage of Participants With CR or PR or Stable Disease (SD) for at Least 6 Months [Clinical Benefit Rate (CBR)] - MBC Population

    CBR was defined as percentage of participants experiencing SD of at least 6 months from the start of treatment plus CR or PR according to the RECIST v1.0 criteria. For TLs: CR- disappearance of all TLs. PR- at least 30% decrease in the sum of LDs of the TLs, taking as a reference the BL sum of LDs. PD- at least 20% increase in the sum of LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more lesions. SD- neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For NTLs: CR- disappearance of all NTLs and normalization of tumor marker levels. SD- persistence of one or more NTLs and/or maintenance of tumor marker level above the normal limits. Percentage of participants= number of participants with CR/PR/SD divided by total number of participants, and then multiplied by 100. 95% CI was determined using the Pearson-Clopper method.

    Time frame: Baseline until disease progression, recurrence or death (up to approximately 3 years)

  7. Duration of Response - MBC Population

    Duration of response was calculated for participants with CR or PR based on the RECIST v1.0 criteria. Duration of response was defined as the time interval between the date the CR or PR was first recorded and the date on which PD was first noted or date of death, whichever occurred first. Participants with no documented PD after CR or PR were censored at the last date at which they were known to have had the CR or PR, respectively. Median duration of response was estimated using the Kaplan-Meier method.

    Time frame: Baseline until disease progression, recurrence or death (up to approximately 3 years)

  8. Percentage of Participants With Pathological CR (pCR) - LABC Population

    The pCR was defined as the absence of invasive neoplastic cells at microscopic examination of the tumor remnants and lymph nodes after surgery following primary systemic therapy.

    Time frame: Within 6 weeks of post-surgery (up to approximately 3 years)

  9. Percentage of Participants With a BOR of CR or PR - LABC Population

    BOR was defined as CR or PR recorded from baseline until disease progression/recurrence according to RECIST v1.0 criteria. For TLs, CR was defined as the disappearance of all TLs, and PR was defined as at least a 30% decrease in the sum of LDs of the TLs, taking as a reference the baseline (BL) sum of LDs. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. Percentage of participants with BOR rate was calculated as the (number of participants with CR or PR) divided by (total number of participants), and then multiplied by 100. The 95% Cl was determined using the Pearson-Clopper method.

    Time frame: Baseline until disease progression, recurrence or death (up to approximately 3 years)

  10. Number of Participants With Anti-Therapeutic Antibody (ATA) Response to Trastuzumab - MBC and LABC Population

    Number of participants with ATA response was reported. Data for this outcome measure was planned to be reported for overall MBC and LABC participants and not by individual treatment arms.

    Time frame: Baseline (Day 1 of Cycle 1), Post baseline (at first follow-up visit [28 days after last dose of study drug][up to approximately 145 weeks])

  11. Maximum Observed Concentration (Cmax) of Serum Trastuzumab Emtansine

    Time frame: Cycle 1: pre-dose (Hour [Hr] 0), 0.25, 4 hrs post end of infusion (EOI) of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)

  12. Apparent Terminal Half-Life (t1/2) of Serum Trastuzumab Emtansine

    Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)

  13. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Serum Trastuzumab Emtansine

    Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)

  14. Clearance (CL) of Serum Trastuzumab Emtansine

    Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)

  15. Volume of Distribution at Steady State (Vss) of Serum Trastuzumab Emtansine

    Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)

  16. Cmax of Total Serum Trastuzumab

    Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)

  17. t1/2 of Total Serum Trastuzumab

    Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)

  18. AUCinf of Total Serum Trastuzumab

    Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)

  19. CL of Total Serum Trastuzumab

    Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)

  20. Vss of Total Serum Trastuzumab

    Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)

  21. Cmax of Plasma N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maytansine (DM1)

    DM1 is the metabolite of trastuzumab emtansine.

    Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)

  22. t1/2 of Plasma DM1

    Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)

  23. AUCinf of Plasma DM1

    Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)

  24. Cmax of Plasma Docetaxel

    Docetaxel infusion duration = 1 hr (as per summary of product characteristics \[SmPC\])

    Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1. Cycle 2: pre-dose (Hr 0), 0.5 hr and 59 min after start of infusion, 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1 (1 cycle = 21 days)

  25. t1/2 of Plasma Docetaxel

    Docetaxel infusion duration = 1 hr (as per SmPC)

    Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1. Cycle 2: pre-dose (Hr 0), 0.5 hr and 59 min after start of infusion, 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1 (1 cycle = 21 days)

  26. AUCinf of Plasma Docetaxel

    Docetaxel infusion duration = 1 hr (as per SmPC)

    Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1. Cycle 2: pre-dose (Hr 0), 0.5 hr and 59 min after start of infusion, 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1 (1 cycle = 21 days)

  27. CL of Plasma Docetaxel

    Docetaxel infusion duration = 1 hr (as per SmPC)

    Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1. Cycle 2: pre-dose (Hr 0), 0.5 hr and 59 min after start of infusion, 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1 (1 cycle = 21 days)

  28. Vss of Plasma Docetaxel

    Docetaxel infusion duration = 1 hr (as per SmPC)

    Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1. Cycle 2: pre-dose (Hr 0), 0.5 hr and 59 min after start of infusion, 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1 (1 cycle = 21 days)

07

Results

Posted Apr 6, 2017

Participant flow

Feasibility Part
Participant flow — Feasibility Part
MilestoneMBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days)MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Over 2 Days)MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Same Day)MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (Same Day)LABC: T-DM1 + Doc (Doublet Regimen)LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen)
Started6636129
Completed1101126
Not completed553503
Withdrew: Progressive disease442300
Withdrew: Physician decision001000
Withdrew: Adverse event110102
Withdrew: Withdrawal by subject000101
Extension Part
Participant flow — Extension Part
MilestoneMBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days)MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Over 2 Days)MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Same Day)MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (Same Day)LABC: T-DM1 + Doc (Doublet Regimen)LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen)
Started00042824
Completed00022419
Not completed000245
Withdrew: Adverse event000144
Withdrew: Progressive disease000100
Withdrew: Non-compliance with drug000001

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicity (DLT) - MBC and LABC Feasibility Population

DLTs included (as per National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] grading): Grade 4 thrombocytopenia, thrombocytopenia of any grade with concurrent hemorrhage or requiring blood platelet transfusion, or thrombocytopenia not recovered by Day 21 to at least 100,000/microliter (mcL); Grade 4 neutropenia lasting for more than 7 days; Febrile neutropenia; Grade greater than or equal to (\>/=) 3 neurotoxicity in the form of peripheral neuropathy or peripheral neurotoxicity not improving to baseline or Grade less than or equal to (\</=) 1 by Day 21; Any non-hematological toxicity of Grade \>/= 3 except for alopecia, fever, and chills, not improving to baseline or Grade \</=1 by Day 21, despite adequate toxicity management; Any subjective intolerable toxicity felt by the investigator to be related to either study treatment; Any other treatment-related toxicity prohibiting the start of the Cycle 2 on Day 22; Fulminant skin rash.

Time frame:
Cycle 1 (up to 21 days)
Reported as:
Number · participants
Number of Participants With Dose Limiting Toxicity (DLT) - MBC and LABC Feasibility Population
participantsMBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days)MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Over 2 Days)MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Same Day)MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (Same Day)LABC: T-DM1 + Doc (Doublet Regimen)LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen)
Number of Participants With Dose Limiting Toxicity (DLT) - MBC and LABC Feasibility Population210122
PrimaryPercentage of Participants With Adverse Events (AEs) or Serious AEs (SAEs) - MBC and LABC Population

An AE is any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

Time frame:
Baseline up to 28 days after last dose for MBC participants and for LABC participants who could not undergo surgery, and up to 6 weeks post-surgery for LABC participants who underwent surgery (maximum up to approximately 3 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) or Serious AEs (SAEs) - MBC and LABC Population
percentage of participantsMBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days)MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Over 2 Days)MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Same Day)MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (Same Day)LABC: T-DM1 + Doc (Doublet Regimen)LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen)
AEs100100100100100100
SAEs33.333.366.740.022.527.3
SecondaryPercentage of Participants With Progression-Free Survival (PFS) Event - MBC Population

PFS was defined as the time interval between the date of the start of treatment and the date of first documentation of progressive disease (PD) or death from any cause, whichever occurred first. Response was based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 (v1.0). For target lesions (TLs), PD was at least a 20 percent (%) increase in the sum of longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more lesions. For non-target lesions (NTLs), PD was the appearance of one or more new lesions and/or unequivocal progression of existing NTLs. Data for participants without PD or death was censored at the time of the last response assessment. Percentage of participants with PFS event was calculated as the (number of participants with PFS event \[PD or death\]) divided by (total number of participants), and then multiplied by 100.

Time frame:
Baseline until disease progression or death (up to approximately 3 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Progression-Free Survival (PFS) Event - MBC Population
percentage of participantsOverall MBC Participants
Percentage of Participants With Progression-Free Survival (PFS) Event - MBC Population60.0
SecondaryPFS - MBC Population

PFS was defined as the time interval between the date of the start of treatment and the date of first documentation of PD or death from any cause, whichever occurred first. Response was based on RECIST v1.0. For TLs, PD was at least a 20 % increase in the sum of LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more lesions. For NTLs, PD was the appearance of one or more new lesions and/or unequivocal progression of existing NTLs. Median PFS time was calculated using Kaplan-Meier estimates. Data for participants without PD or death was censored at the time of the last response assessment.

Time frame:
Baseline until disease progression or death (up to approximately 3 years)
Reported as:
Median · months
PFS - MBC Population
monthsOverall MBC Participants
PFS - MBC Population13.8 (1.6 to 33.5)
SecondaryPercentage of Participants With a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) - MBC Population

BOR was defined as CR or PR recorded from baseline until disease progression/recurrence according to RECIST v1.0 criteria. For TLs, CR was defined as the disappearance of all TLs, and PR was defined as at least a 30% decrease in the sum of LDs of the TLs, taking as a reference the baseline (BL) sum of LDs. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. Percentage of participants with BOR rate was calculated as the (number of participants with CR or PR) divided by (total number of participants), and then multiplied by 100. The 95% confidence interval (Cl) was determined using the Pearson-Clopper method.

Time frame:
Baseline until disease progression or recurrence (up to approximately 3 years)
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) - MBC Population
percentage of participantsOverall MBC Participants
Percentage of Participants With a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) - MBC Population80.0 (59.3 to 93.2)
SecondaryPercentage of Participants With Treatment Failure - MBC Population

Treatment failure was defined as the discontinuation of treatment for any reason, including the following qualifying events: PD, death from any cause, withdrawal from study treatment, or initiation of nonprotocol anti-cancer therapy. Percentage of participants with treatment failure was calculated as the (number of participants with treatment failure) divided by (total number of participants), and then multiplied by 100.

Time frame:
Baseline until end of treatment (up to 39.8 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Failure - MBC Population
percentage of participantsOverall MBC Participants
Percentage of Participants With Treatment Failure - MBC Population64.0
SecondaryTime to Treatment Failure (TTF) - MBC Population

TTF was defined as the time interval between the date of start of treatment and the date of PD, death from any cause, withdrawal from study treatment, or initiation of non-protocol anti-cancer therapy, whichever occurred first. Participants without an event at the time of the analysis were censored at the date of the last follow-up assessment. Median TTF was estimated using the Kaplan-Meier method.

Time frame:
Baseline until end of treatment (up to 39.8 months)
Reported as:
Median · months
Time to Treatment Failure (TTF) - MBC Population
monthsOverall MBC Participants
Time to Treatment Failure (TTF) - MBC Population13.8 (1.4 to 39.8)
SecondaryPercentage of Participants With CR or PR or Stable Disease (SD) for at Least 6 Months [Clinical Benefit Rate (CBR)] - MBC Population

CBR was defined as percentage of participants experiencing SD of at least 6 months from the start of treatment plus CR or PR according to the RECIST v1.0 criteria. For TLs: CR- disappearance of all TLs. PR- at least 30% decrease in the sum of LDs of the TLs, taking as a reference the BL sum of LDs. PD- at least 20% increase in the sum of LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more lesions. SD- neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For NTLs: CR- disappearance of all NTLs and normalization of tumor marker levels. SD- persistence of one or more NTLs and/or maintenance of tumor marker level above the normal limits. Percentage of participants= number of participants with CR/PR/SD divided by total number of participants, and then multiplied by 100. 95% CI was determined using the Pearson-Clopper method.

Time frame:
Baseline until disease progression, recurrence or death (up to approximately 3 years)
Reported as:
Number · percentage of participants
Percentage of Participants With CR or PR or Stable Disease (SD) for at Least 6 Months [Clinical Benefit Rate (CBR)] - MBC Population
percentage of participantsOverall MBC Participants
Percentage of Participants With CR or PR or Stable Disease (SD) for at Least 6 Months [Clinical Benefit Rate (CBR)] - MBC Population92.0 (74.0 to 99.0)
SecondaryDuration of Response - MBC Population

Duration of response was calculated for participants with CR or PR based on the RECIST v1.0 criteria. Duration of response was defined as the time interval between the date the CR or PR was first recorded and the date on which PD was first noted or date of death, whichever occurred first. Participants with no documented PD after CR or PR were censored at the last date at which they were known to have had the CR or PR, respectively. Median duration of response was estimated using the Kaplan-Meier method.

Time frame:
Baseline until disease progression, recurrence or death (up to approximately 3 years)
Reported as:
Median · months
Duration of Response - MBC Population
monthsOverall MBC Participants
Duration of Response - MBC Population12.4 (3.9 to 32.7)
SecondaryPercentage of Participants With Pathological CR (pCR) - LABC Population

The pCR was defined as the absence of invasive neoplastic cells at microscopic examination of the tumor remnants and lymph nodes after surgery following primary systemic therapy.

Time frame:
Within 6 weeks of post-surgery (up to approximately 3 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Pathological CR (pCR) - LABC Population
percentage of participantsLABC: T-DM1 + Doc (Doublet Regimen)LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen)
Percentage of Participants With Pathological CR (pCR) - LABC Population60.0 (43.3 to 75.1)60.6 (42.1 to 77.1)
SecondaryPercentage of Participants With a BOR of CR or PR - LABC Population

BOR was defined as CR or PR recorded from baseline until disease progression/recurrence according to RECIST v1.0 criteria. For TLs, CR was defined as the disappearance of all TLs, and PR was defined as at least a 30% decrease in the sum of LDs of the TLs, taking as a reference the baseline (BL) sum of LDs. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. Percentage of participants with BOR rate was calculated as the (number of participants with CR or PR) divided by (total number of participants), and then multiplied by 100. The 95% Cl was determined using the Pearson-Clopper method.

Time frame:
Baseline until disease progression, recurrence or death (up to approximately 3 years)
Reported as:
Number · percentage of participants
Percentage of Participants With a BOR of CR or PR - LABC Population
percentage of participantsLABC: T-DM1 + Doc (Doublet Regimen)LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen)
Percentage of Participants With a BOR of CR or PR - LABC Population70.0 (53.5 to 83.4)51.5 (33.5 to 69.2)
SecondaryNumber of Participants With Anti-Therapeutic Antibody (ATA) Response to Trastuzumab - MBC and LABC Population

Number of participants with ATA response was reported. Data for this outcome measure was planned to be reported for overall MBC and LABC participants and not by individual treatment arms.

Time frame:
Baseline (Day 1 of Cycle 1), Post baseline (at first follow-up visit [28 days after last dose of study drug][up to approximately 145 weeks])
Reported as:
Number · participants
Number of Participants With Anti-Therapeutic Antibody (ATA) Response to Trastuzumab - MBC and LABC Population
participantsOverall MBC and LABC Participants
Baseline3
Post-baseline3
SecondaryMaximum Observed Concentration (Cmax) of Serum Trastuzumab Emtansine
Time frame:
Cycle 1: pre-dose (Hour [Hr] 0), 0.25, 4 hrs post end of infusion (EOI) of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Maximum Observed Concentration (Cmax) of Serum Trastuzumab Emtansine
micrograms per milliliter (mcg/mL)MBC: T-DM1 2.4 mg/kgMBC: T-DM1 3.6 mg/kgLABC: T-DM1 3.6 mg/kg
Cycle 178.6 ± 16.676.2 ± 36.485.7 ± 15.3
Cycle 278.7 ± 16.793.7 ± 27.680.2 ± 18.4
SecondaryApparent Terminal Half-Life (t1/2) of Serum Trastuzumab Emtansine
Time frame:
Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Reported as:
Mean · days
Apparent Terminal Half-Life (t1/2) of Serum Trastuzumab Emtansine
daysMBC: T-DM1 2.4 mg/kgMBC: T-DM1 3.6 mg/kgLABC: T-DM1 3.6 mg/kg
Cycle 12.79 ± 0.6373.45 ± 0.7793.46 ± 0.558
Cycle 23.14 ± 0.5743.85 ± 0.5683.62 ± 0.516
SecondaryArea Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Serum Trastuzumab Emtansine
Time frame:
Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Reported as:
Mean · day*mcg/mL
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Serum Trastuzumab Emtansine
day*mcg/mLMBC: T-DM1 2.4 mg/kgMBC: T-DM1 3.6 mg/kgLABC: T-DM1 3.6 mg/kg
Cycle 1396 ± 124447 ± 144442 ± 90.7
Cycle 2471 ± 94.5556 ± 223488 ± 123
SecondaryClearance (CL) of Serum Trastuzumab Emtansine
Time frame:
Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Reported as:
Mean · milliliters/day/kilogram (mL/day/kg)
Clearance (CL) of Serum Trastuzumab Emtansine
milliliters/day/kilogram (mL/day/kg)MBC: T-DM1 2.4 mg/kgMBC: T-DM1 3.6 mg/kgLABC: T-DM1 3.6 mg/kg
Cycle 18.94 ± 128.87 ± 2.968.48 ± 1.86
Cycle 25.21 ± 1.277.16 ± 2.957.68 ± 2.73
SecondaryVolume of Distribution at Steady State (Vss) of Serum Trastuzumab Emtansine
Time frame:
Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Reported as:
Mean · mL/kg
Volume of Distribution at Steady State (Vss) of Serum Trastuzumab Emtansine
mL/kgMBC: T-DM1 2.4 mg/kgMBC: T-DM1 3.6 mg/kgLABC: T-DM1 3.6 mg/kg
Cycle 122.1 ± 6.7433.2 ± 9.1333.2 ± 8.36
Cycle 217.7 ± 4.7331.4 ± 16.928.8 ± 9.32
SecondaryCmax of Total Serum Trastuzumab
Time frame:
Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Reported as:
Mean · mcg/mL
Cmax of Total Serum Trastuzumab
mcg/mLMBC: T-DM1 2.4 mg/kgMBC: T-DM1 3.6 mg/kgLABC: T-DM1 3.6 mg/kg
Cycle 188.7 ± 22.689.2 ± 47.4120 ± 46.6
Cycle 285.8 ± 17.597.7 ± 29.4113 ± 43.8
Secondaryt1/2 of Total Serum Trastuzumab
Time frame:
Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Reported as:
Mean · days
t1/2 of Total Serum Trastuzumab
daysMBC: T-DM1 2.4 mg/kgMBC: T-DM1 3.6 mg/kgLABC: T-DM1 3.6 mg/kg
Cycle 16.44 ± 2.66.38 ± 1.418.12 ± 4.2
Cycle 26.67 ± 1.927.83 ± 1.689.91 ± 5.01
SecondaryAUCinf of Total Serum Trastuzumab
Time frame:
Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Reported as:
Mean · day*mcg/mL
AUCinf of Total Serum Trastuzumab
day*mcg/mLMBC: T-DM1 2.4 mg/kgMBC: T-DM1 3.6 mg/kgLABC: T-DM1 3.6 mg/kg
Cycle 1785 ± 429707 ± 2011210 ± 856
Cycle 2809 ± 3081040 ± 3591570 ± 1180
SecondaryCL of Total Serum Trastuzumab
Time frame:
Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Reported as:
Mean · mL/day/kg
CL of Total Serum Trastuzumab
mL/day/kgMBC: T-DM1 2.4 mg/kgMBC: T-DM1 3.6 mg/kgLABC: T-DM1 3.6 mg/kg
Cycle 16.78 ± 13.35.45 ± 1.464.22 ± 2.13
Cycle 23.32 ± 1.533.71 ± 1.233.38 ± 2.11
SecondaryVss of Total Serum Trastuzumab
Time frame:
Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Reported as:
Mean · mL/kg
Vss of Total Serum Trastuzumab
mL/kgMBC: T-DM1 2.4 mg/kgMBC: T-DM1 3.6 mg/kgLABC: T-DM1 3.6 mg/kg
Cycle 127 ± 7.1641.3 ± 9.2436.5 ± 12.7
Cycle 224.6 ± 5.0536.4 ± 11.335.2 ± 12
SecondaryCmax of Plasma N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maytansine (DM1)

DM1 is the metabolite of trastuzumab emtansine.

Time frame:
Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Reported as:
Mean · nanograms per milliliter (ng/mL)
Cmax of Plasma N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maytansine (DM1)
nanograms per milliliter (ng/mL)MBC: T-DM1 2.4 mg/kgMBC: T-DM1 3.6 mg/kgLABC: T-DM1 3.6 mg/kg
Cycle 13.55 ± 1.63.42 ± 0.9444.51 ± 1.38
Cycle 23.34 ± 0.8153.9 ± 1.194.65 ± 1.57
Secondaryt1/2 of Plasma DM1
Time frame:
Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Reported as:
Mean · days
t1/2 of Plasma DM1
daysMBC: T-DM1 2.4 mg/kgMBC: T-DM1 3.6 mg/kgLABC: T-DM1 3.6 mg/kg
Cycle 11.12 ± 0.7021.2 ± 0.9851.87 ± 1.63
Cycle 23.75 ± 0.9122.913.32 ± 0.7
SecondaryAUCinf of Plasma DM1
Time frame:
Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Reported as:
Mean · day*ng/mL
AUCinf of Plasma DM1
day*ng/mLMBC: T-DM1 2.4 mg/kgMBC: T-DM1 3.6 mg/kgLABC: T-DM1 3.6 mg/kg
Cycle 15.72 ± 5.165.01 ± 2.549.38 ± 9.33
Cycle 217.8 ± 4.62018.5 ± 4.28
SecondaryCmax of Plasma Docetaxel

Docetaxel infusion duration = 1 hr (as per summary of product characteristics \[SmPC\])

Time frame:
Cycle 1: pre-dose (Hr 0), 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1. Cycle 2: pre-dose (Hr 0), 0.5 hr and 59 min after start of infusion, 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1 (1 cycle = 21 days)
Reported as:
Mean · ng/mL
Cmax of Plasma Docetaxel
ng/mLMBC: Docetaxel 75 mg/m^2MBC: Docetaxel 60 mg/m^2LABC: Docetaxel 60 mg/m^2LABC: Docetaxel 75 mg/m^2LABC: Docetaxel 100 mg/m^2
Cycle 1500 ± 2161300 ± 8291470 ± 5511710 ± 4262950 ± 1540
Cycle 2791 ± 6371320 ± 8261590 ± 4411960 ± 5522790 ± 979
Secondaryt1/2 of Plasma Docetaxel

Docetaxel infusion duration = 1 hr (as per SmPC)

Time frame:
Cycle 1: pre-dose (Hr 0), 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1. Cycle 2: pre-dose (Hr 0), 0.5 hr and 59 min after start of infusion, 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1 (1 cycle = 21 days)
Reported as:
Mean · hours (hr)
t1/2 of Plasma Docetaxel
hours (hr)MBC: Docetaxel 75 mg/m^2MBC: Docetaxel 60 mg/m^2LABC: Docetaxel 60 mg/m^2LABC: Docetaxel 75 mg/m^2LABC: Docetaxel 100 mg/m^2
Cycle 16.83 ± 4.225.17 ± 4.024.25 ± 5.618.29 ± 5.758.76 ± 3.82
Cycle 27.7 ± 4.157.88 ± 6.185.9 ± 3.836.69 ± 5.557.24 ± 3.58
SecondaryAUCinf of Plasma Docetaxel

Docetaxel infusion duration = 1 hr (as per SmPC)

Time frame:
Cycle 1: pre-dose (Hr 0), 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1. Cycle 2: pre-dose (Hr 0), 0.5 hr and 59 min after start of infusion, 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1 (1 cycle = 21 days)
Reported as:
Mean · hr*ng/mL
AUCinf of Plasma Docetaxel
hr*ng/mLMBC: Docetaxel 75 mg/m^2MBC: Docetaxel 60 mg/m^2LABC: Docetaxel 60 mg/m^2LABC: Docetaxel 75 mg/m^2LABC: Docetaxel 100 mg/m^2
Cycle 11050 ± 4751560 ± 8741540 ± 4212140 ± 6694020 ± 2120
Cycle 21700 ± 11901710 ± 8753260 ± 51002420 ± 8873840 ± 1930
SecondaryCL of Plasma Docetaxel

Docetaxel infusion duration = 1 hr (as per SmPC)

Time frame:
Cycle 1: pre-dose (Hr 0), 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1. Cycle 2: pre-dose (Hr 0), 0.5 hr and 59 min after start of infusion, 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1 (1 cycle = 21 days)
Reported as:
Mean · liters/hour/square meter (L/hr/m^2)
CL of Plasma Docetaxel
liters/hour/square meter (L/hr/m^2)MBC: Docetaxel 75 mg/m^2MBC: Docetaxel 60 mg/m^2LABC: Docetaxel 60 mg/m^2LABC: Docetaxel 75 mg/m^2LABC: Docetaxel 100 mg/m^2
Cycle 182.2 ± 32.658.3 ± 40.942.8 ± 16.439.5 ± 16.830.5 ± 14.5
Cycle 259 ± 29.951.2 ± 38.532.6 ± 13.133.6 ± 11.927.9 ± 9.13
SecondaryVss of Plasma Docetaxel

Docetaxel infusion duration = 1 hr (as per SmPC)

Time frame:
Cycle 1: pre-dose (Hr 0), 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1. Cycle 2: pre-dose (Hr 0), 0.5 hr and 59 min after start of infusion, 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1 (1 cycle = 21 days)
Reported as:
Mean · liters per square meter (L/m^2)
Vss of Plasma Docetaxel
liters per square meter (L/m^2)MBC: Docetaxel 75 mg/m^2MBC: Docetaxel 60 mg/m^2LABC: Docetaxel 60 mg/m^2LABC: Docetaxel 75 mg/m^2LABC: Docetaxel 100 mg/m^2
Cycle 1530 ± 398203 ± 27575 ± 113126 ± 86.7116 ± 73.3
Cycle 2380 ± 257253 ± 23493.2 ± 64.779 ± 53.684.8 ± 39.1

Adverse events

Collected over Baseline up to 28 days after last dose for MBC participants and for LABC participants who could not undergo surgery, and up to 6 weeks post-surgery for LABC participants who underwent surgery (maximum up to approximately 3 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days)—2/6 (33.3%)6/6 (100%)
MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Over 2 Days)—2/6 (33.3%)6/6 (100%)
MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Same Day)—2/3 (66.7%)3/3 (100%)
MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (Same Day)—4/10 (40%)10/10 (100%)
LABC: T-DM1 + Doc (Doublet Regimen)—9/40 (22.5%)40/40 (100%)
LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen)—9/33 (27.3%)33/33 (100%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventMBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days)MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Over 2 Days)MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Same Day)MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (Same Day)LABC: T-DM1 + Doc (Doublet Regimen)LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen)
AnxietyPsychiatric disorders0/60/61/30/100/400/33
Febrile neutropeniaBlood and lymphatic system disorders1/61/61/30/101/401/33
Thrombosis in deviceGeneral disorders1/61/60/30/100/400/33
NeutropeniaBlood and lymphatic system disorders0/61/60/30/101/402/33
ThrombocytopeniaBlood and lymphatic system disorders1/60/60/30/101/401/33
Hepatocellular injuryHepatobiliary disorders1/60/60/30/100/401/33
CholecystitisHepatobiliary disorders1/60/60/30/100/400/33
Viral infectionInfections and infestations0/61/60/30/101/401/33
HaematomaVascular disorders0/60/60/31/100/400/33
Tibia fractureInjury, poisoning and procedural complications0/60/60/31/100/400/33
Most frequent other events
Showing 10 of 202
Most frequent other events
EventMBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days)MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Over 2 Days)MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Same Day)MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (Same Day)LABC: T-DM1 + Doc (Doublet Regimen)LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen)
AstheniaGeneral disorders6/65/61/36/1025/4020/33
NeutropeniaBlood and lymphatic system disorders6/65/61/37/1011/4012/33
ConstipationGastrointestinal disorders1/61/63/33/1019/4011/33
PyrexiaGeneral disorders1/65/60/32/108/4010/33
EpistaxisRespiratory, thoracic and mediastinal disorders2/65/61/36/1021/4019/33
LeukopeniaBlood and lymphatic system disorders5/63/61/34/103/403/33
LymphopeniaBlood and lymphatic system disorders5/61/60/33/103/404/33
NauseaGastrointestinal disorders1/65/61/34/1016/4016/33
ThrombocytopeniaBlood and lymphatic system disorders4/64/60/38/109/407/33
DyspnoeaRespiratory, thoracic and mediastinal disorders1/62/62/34/104/401/33

Baseline characteristics

All participants who received at least one dose of study medication were included.

Age, Continuous
Age, Continuous(years)MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days)MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Over 2 Days)MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Same Day)MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (Same Day)LABC: T-DM1 + Doc (Doublet Regimen)LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen)Total
Mean43 ± 7.1650.7 ± 4.8457 ± 12.1248 ± 9.3948.6 ± 9.7354.2 ± 11.4350.4 ± 10.39
Sex: Female, Male
Sex: Female, Male(Participants)MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days)MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Over 2 Days)MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Same Day)MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (Same Day)LABC: T-DM1 + Doc (Doublet Regimen)LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen)Total
Female66310403398
Male0000000
08

Study locations

8 sites
  • Charlotte, North Carolina 28203, United States
  • Houston, Texas 77005, United States
  • Dijon, 21079, France
  • Saint Herblain, 44805, France
  • Barcelona, 08003, Spain
  • Madrid, 28007, Spain
  • Madrid, 28040, Spain
  • Dundee, DD1 9SY, United Kingdom
09

References and documents

Publications

  • Martin M, Fumoleau P, Dewar JA, Albanell J, Limentani SA, Campone M, Chang JC, Patre M, Strasak A, de Haas SL, Xu J, Garcia-Saenz JA. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. Ann Oncol. 2016 Jul;27(7):1249-56. doi: 10.1093/annonc/mdw157. Epub 2016 Apr 6. PubMed 27052654 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2009 to primary completion in Oct 2013, 51 months.

Results were first posted in Apr 2017, 3 years 6 months after primary completion.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's 51 months is below that.

Counting every sponsor, half of 327 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2009
First posted
Jul 8, 2009
StartActual
Jul 2009
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Apr 6, 2017
Last update
Apr 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00934856
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 8, 2009
Start date
Jul 2009
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Apr 6, 2017
Last update
Apr 6, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Ado-Trastuzumab Emtansine

Start the discussion